|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
Because Bristol-Myers Squibb (BMY) is acquiring Celgene, starting with Q1 2019 I will only be covering BMY.
Bristol-Myers Squibb Stock To Be Issued For Celgene: To Keep or Not to Keep [Seeking Alpha, January 15, 2019]
Five Reasons Celgene Will Recover [Seeking Alpha, June 1, 2018]
Celgene is Oversold [Seeking Alpha, 11/30/2017]
[older stories are below the Conference Summary table]
2019 |
|||
 |
|
||
Jan. 31, 2019 |
April 25, 2019 |
July 30, 2019 |
oct. 31, 2019 |
Q4 2018 |
Q1 2019 |
Q2 2019 |
Q3 2019 |
2018 |
|||
|
|
|
|
Jan. 25, 2018 |
May 4, 2018 |
July 26, 2018 |
Oct. 25, 2018 |
Q4 2017 |
Q1 2018 |
Q2 2018 |
Q3 2018 |
2017 |
|||
|
|
|
|
01/26/2017 |
04/27/2017 |
July 27, 2017 |
Oct. 26, 2017 |
Q4 2016 |
Q1 2017 |
Q2 2017 |
Q3 2017 |
2016 |
|||
|
|
|
|
01/28/2015 |
04/28/2016 |
07/28/201 |
10/27/2016 |
Q4 2015 |
Q1 2016 |
Q2 2016 |
Q3 2016 |
2015 |
|||
|
|
|
|
01/29/2015 |
4/30/2015 |
07/23/2015 |
10/05/2015 |
Q4 2014 |
Q1 2015 |
Q2 2015 |
Q3 2015 |
2014 |
|||
|
|
|
|
01/30/2014 |
4/24/2014 |
07/24/2014 |
10/23/2014 |
Q4 2013 |
Q1 2014 |
Q2 2014 |
Q3 2014 |
2013 |
|||
|
|
|
|
01/24/2013 |
04/25/2013 |
07/25/2013 |
10/24/2013 |
Q4 2012 |
Q1 2013 |
Q2 2013 |
Q3 2013 |
2012 |
|||
|
|
|
|
01/26/2012 |
4/26/2012 |
07/26/2012 |
10/25/2012 |
Q4 2011 |
Q1 2012 |
Q2 2012 |
Q3 2012 |
2011 |
|||
|
|
|
|
01/27/2011 |
04/28/2011 |
07/28/2011 |
10/27/2011 |
Q4 2010 |
Q1 2011 |
Q2 2011 |
Q3 2011 |
2010 |
|||
|
|
|
|
01/28/2010 |
04/29/2010 |
07/29/2010 |
10/28/2010 |
Q4 2009 |
Q1 2010 |
Q2 2010 |
Q3 2010 |
2009 |
|||
|
|
|
|
01/29/2009 |
04/30/2009 |
07/23/2009 |
10/22/2009 |
Q4 2008 |
Q1 2009 |
Q2 2009 |
Q3 2009 |
2008
|
|||
|
|
|
|
10/23/2008 |
07/24/2008 |
05/08/2008 |
01/31/2008 |
Q3 2008 |
Q2 2008 |
Q1 2008 |
Q4 2007 |
2007 |
|||
|
|
|
|
10/25/2007 |
07/26/2007 |
05/03/2007 |
|
Q3 2007 |
Q2 2007 |
Q1 2007 |
|
Celgene is a biotechnology company; products include Thalomid, Revlimid, Abraxane and Pomalyst.
Celgene Catalysts for 2016 [December 31, 2015 at Seeking Alpha]
Celgene Rapid Growth Ahead for 2016 through 2020 [July 7, 2015 at Seeking Alpha]
Celgene Announces 2015 and Long-Term Financial Outlook [January 12, 2015 press release]
Celgene Stock Price: Bubbly? [December 1, 2014 at Seeking Alpha]
Celgene In 2015: $200 Per Share [April 29, 2014 at Seeking Alpha]
Celgene in 2017: $375 per share or more [January 14, 2014]
Celgene Up Over 100% in a Year. Still a Buy? [July 30, 2013 at Seeking Alpha]
Celgene Sees Revenue Doubling by 2017 [January 26, 2013]
Celgene Up on Psoriatic Arthritis Data [September 6, 2012]
Gilead Sciences, Biogen Idec, and Celgene [August 13, 2012]
Celgene Withdraws Revlimid Extension in Europe [June 21, 2012 Celgene press release]
Celgene Short and Long Views [April 27, 2012]
Celgene Q3 shows model strength [Nobember 7, 2011]
Celgene Readies Arsenal [August 2, 2011]
Celgene (CELG) ASH Data Points [December 11, 2010]
Celgene Gathers Momentum [November 1, 2010]
Celgene Q1 Advance on Revlimid, Vidaza [May 5, 2010]
Celgene Q4 2009 Earnings and Revenue Estimates [January 11, 2010]
Celgene to Grow Rapidly [September 7, 2008]
Celgene Data for Revlimid, Vidaza, Amrubicin [June 15, 2008]
Celgene Optimism [February 4, 2008]
Celgene (CELG) and Pharmion (PHRM) [November 24, 2007 blog]
Pharmion Acquisition [November 19, 2007 press release]
Celgene in Hypergrowth [May 23, 2007 blog]
Celgene Web site:
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but its possible. Before making or terminating an investment you should always verify any factual basis of your decision.